Getting on Ozempic for weight loss is possible, but it’s not as straightforward as asking your doctor for a prescription. Ozempic is not FDA-approved for weight loss. It’s approved for managing type 2 diabetes and reducing cardiovascular risk in people with type 2 diabetes. When doctors prescribe it for weight loss alone, they’re using it “off-label,” which changes how you access it, what you’ll pay, and whether your insurance will help.
Why Ozempic Isn’t the “Weight Loss Version”
Ozempic and Wegovy contain the same active ingredient, semaglutide, but they’re approved for different purposes. Wegovy is the only semaglutide product FDA-approved for weight management, and it comes in a higher maximum dose (2.4 mg versus Ozempic’s 2 mg). Wegovy is approved for adults and children 12 and older who meet specific weight criteria.
Because of this distinction, your doctor may steer you toward Wegovy if weight loss is your primary goal. But supply issues, cost differences, and insurance coverage sometimes make Ozempic the more practical option. Both drugs work the same way: they mimic a hormone that slows digestion, reduces appetite, and helps regulate blood sugar. The weight loss effect is real with both versions.
Who Qualifies for Semaglutide
For weight management specifically, clinicians typically follow criteria based on body mass index. You generally need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or cardiovascular disease. You also need to be 18 or older.
If you have type 2 diabetes, you have a clearer path to an Ozempic prescription specifically, since that’s its approved use. Your doctor can prescribe it on-label, and insurance is far more likely to cover it. The weight loss, in that case, is treated as a beneficial side effect rather than the primary reason for the prescription.
The Practical Steps to Get a Prescription
Start with your primary care doctor or schedule an appointment with a weight management specialist or endocrinologist. Come prepared to discuss your weight history, any previous diet or exercise efforts, and your current health conditions. Your doctor will check your BMI, review your bloodwork (especially blood sugar levels), and assess whether semaglutide is appropriate given your medical history.
If your doctor agrees that semaglutide makes sense, they’ll decide whether to prescribe Ozempic off-label or Wegovy on-label. This decision often depends on what your insurance covers and what’s available at your pharmacy. Some telehealth platforms now offer weight management consultations and can prescribe semaglutide after a virtual visit, which has made access easier in many cases.
There are a few conditions that rule out semaglutide entirely. If you have a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma, or a rare condition called Multiple Endocrine Neoplasia syndrome type 2, semaglutide is not safe for you. A history of pancreatitis is also a concern your doctor will want to discuss.
What Insurance Actually Covers
This is where many people hit a wall. Most insurance plans require prior authorization for Ozempic, and that authorization process is built around diabetes, not weight loss. A typical insurer like Aetna, for example, requires a diagnosis of type 2 diabetes plus at least one of the following: an inadequate response to metformin, an A1C of 7.5% or greater when combination therapy is needed, or established cardiovascular disease.
If you don’t have type 2 diabetes, most commercial insurers will deny coverage for Ozempic. Some plans cover Wegovy for weight management, but many don’t, and those that do often impose their own prior authorization requirements. Without insurance, both medications cost over $1,000 per month at retail price, though manufacturer savings programs and pharmacy discount cards can reduce this significantly for some people.
If your insurance denies coverage, your options include appealing the decision with supporting documentation from your doctor, switching to Wegovy if your plan covers it for weight management, using a manufacturer coupon if you’re commercially insured, or paying out of pocket through discount pharmacy programs.
How the Medication Is Started
Ozempic is a once-weekly injection you give yourself using a pre-filled pen, typically in the abdomen, thigh, or upper arm. The dose starts low and increases gradually over several months to minimize side effects.
The standard schedule looks like this:
- Weeks 1 through 4: 0.25 mg once weekly (this is not a treatment dose; it lets your body adjust)
- Weeks 5 through 8: 0.5 mg once weekly
- Week 9 onward: 1 mg once weekly, if more effect is needed
- Later adjustment: up to 2 mg once weekly, the maximum Ozempic dose
Each increase happens after at least four weeks at the current dose. Your doctor will check in during this titration period to see how you’re tolerating the medication and whether the dose needs adjusting. Most people don’t start seeing significant weight loss until they reach the 1 mg dose or higher, so patience during the first couple of months is important.
Side Effects to Expect
Gastrointestinal symptoms are the most common reason people struggle with semaglutide, especially during dose increases. In clinical data, roughly 21.5% of people taking semaglutide experienced nausea, about 9% had vomiting, and around 8% reported constipation. Diarrhea and indigestion each affected about 9 to 11% of users.
These side effects are usually worst in the first few weeks after each dose increase and tend to improve as your body adjusts. Eating smaller meals, avoiding fatty or greasy foods, and staying hydrated can help. If nausea becomes severe or doesn’t improve, your doctor may slow down the dose increases or hold you at a lower dose longer. Some people find that they tolerate 0.5 mg or 1 mg well but have trouble at higher doses.
Current Availability
Semaglutide products were in shortage from 2022 through early 2025 due to surging demand. As of February 2025, the FDA determined that the shortage of semaglutide injection products is resolved, and as of April 2025, semaglutide no longer appears on the FDA’s drug shortage list. This means pharmacies should be able to fill prescriptions reliably, though individual pharmacies may still occasionally have stock gaps.
The resolution of the shortage also affects compounded versions of semaglutide, which some people turned to during the supply crunch. The FDA has been tightening rules around compounded semaglutide now that branded supply has stabilized, so compounded options may become harder to access going forward.